跳至主要内容
临床试验/CTRI/2019/10/021821
CTRI/2019/10/021821
招募中
4 期

Evaluation of safety and efficacy of a proprietary digestive and carminative oral syrup formulationin the management of indigestion functional dyspepsia flatulence & anorexia in adults

East India Pharmaceutical Works Limited0 个研究点目标入组 0 人待定

概览

阶段
4 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
East India Pharmaceutical Works Limited
状态
招募中
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

发起方
East India Pharmaceutical Works Limited

入排标准

入选标准

  • i. Adult subjects of both sexes between 18\-65 yrs of age.
  • ii. Presence of symptoms suggestive of indigestion, functional dyspepsia, flatulence \& anorexia, such asâ??post prandial fullness, early satiety, upper abdominal (epigastric) pain/burning/discomfort, bloating \& abdominal distension, excessive flatulence \&/or belching, nausea, vomiting, excessive regurgitation, heartburn/reflux.
  • iii. Willing to provide written informed consent.

排除标准

  • i. Pregnant or nursing women.
  • ii. Presence of heartburn as the only predominant symptom, dysphagia or jaundice.
  • iii. Suspected/known past history of peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), GI bleeding from any source, major GI/abdominal surgery (except appendicectomy).
  • iv. History, suspicion or proven presence of any other organic gastroduodenal, esophageal or hepato\-pancreatico\-biliary lesions including esophagitis, gastric atrophy, erosive gastritis, pancreatitis, cholecystitis, cholelithiasis, etc.
  • v. Chronic/recent use (within past 3 mths) of NSAIDs, corticosteroids or other drugs affecting gastric acid secretion or presence of chronic diseases requiring intermittent or chronic treatment with these drugs.
  • vi. Suffering from inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or any other form of diarrhoea (loose stools) which could be of infectious origin.
  • vii. Suffering from any other symptoms suggestive of an ongoing infection.
  • viii. Known allergies to any constituents of the study medications.
  • ix. History of acute coronary syndrome, cerebrovascular events, end stage renal disease, or other serious diseases of vital organs like heart, kidney, liver, bone marrow, etc.
  • x. History of underlying serious psychiatric illnesses or alcohol/substance abuse.

结局指标

主要结局

未指定

相似试验